GERD Market Analysis, Size, Share & Growth Forecast 2026–2034

Vonoprazan Voquezna P-CAB Ionic K+ Competition 93 Versus 85 Percent Erosive Oesophagitis Healing at 8 Weeks and 90 Versus 76 Percent 6-Month Healing Maintenance Versus Lansoprazole Has Established the Potassium-Competitive Blocker as Superior Acid Suppression Over the PPI Standard.Takeda's vonoprazan Voquezna demonstrated non-inferior healing rates in erosive esophagitis with superior speed of healing and heartburn resolution at 1 and 2 weeks versus lansoprazole in PHALCON-EE, establishing the P-CAB class as producing faster symptom relief than PPI through acid suppression that is pH-independent and persists through the overnight period where PPI suppression wanes due to the short half-life of covalent H+/K+ ATPase inhibition. The P-CAB mechanism inhibits the proton pump in both active and inactive states without requiring meal-time dosing coordination, achieving more consistent 24-hour acid control than omeprazole or esomeprazole whose efficacy depends on acid secretion activation occurring within 60 minutes of administration. Vonoprazan's clinical programme is extending into H. pylori eradication where the superior acid suppression duration significantly improves antibiotic action and achieves H. pylori eradication rates of 84% for triple therapy compared with 79% for clarithromycin-lansoprazole, supporting vonoprazan as the preferred acid suppressant for H. pylori eradication combination regimens.

Vonoprazan First-Dose pH Efficacy Without Meal-Dependent Acid Activation That PPIs Require for Optimal Covalent Sulfenamide Conversion Has Provided the Dosing Flexibility Advantage Allowing Any-Time Administration Regardless of the Meal Timing That PPI Prescribing Requires.The Lyon Consensus diagnostic criteria published in 2021 by international reflux disease specialists standardised pH-impedance diagnostic thresholds and defined grades of pathological reflux evidence that guide treatment intensity, providing a framework for specialist management that reduces both under-treatment of erosive GERD and over-treatment of functional oesophageal symptoms with long-term PPI therapy. Smartpill pH capsule wireless monitoring and Bravo pH capsule extended 96-hour recording have improved the diagnostic sensitivity of ambulatory monitoring, enabling more complete characterisation of physiological and meal-time acid exposure patterns that single 24-hour catheter studies cannot capture in patients with intermittent symptom triggers.

LINX Magnetic Sphincter Augmentation Titanium Bead Ring Reinforcing the Lower Oesophageal Barrier Has Provided the Minimally Invasive Surgical Alternative to Nissen Fundoplication for the GERD Patient Failing Maximised Medical Therapy Who Prefers the Reversible Augmentation Over the Fundoplication Wrap.Laparoscopic Roux-en-Y gastric bypass eliminates GERD in approximately 80-85% of patients as a metabolic consequence of altered gastric anatomy that reduces acid exposure, and the GERD elimination is the primary driver of reflux-related quality of life improvement after RYGB that antireflux fundoplication does not fully replicate. The LINX magnetic sphincter augmentation device from Ethicon provides a minimally invasive alternative to Nissen fundoplication that has demonstrated superior GERD-HRQL improvement and faster return to solid food intake, with 87% of patients off daily PPI at 10 years in the CALIBER extension study. Endoscopic anti-reflux mucosal resection and transoral incisionless fundoplication from Medigus MUSE system provide less invasive endoscopic GERD management for patients with mild hiatus hernia who are not surgical candidates, expanding the procedural anti-reflux market beyond open and laparoscopic surgery to endoscopy suite-based interventions.

For related market intelligence, see the Gastroenterology Drug Market.